Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance and optimize the ability of each product candidate in our pipeline.
Our improved drug-delivery systems, and targeted drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments and treatments for CNS disorders.
Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.
Virpax also has global rights to the proprietary MET enkephalin formulation to manage Post Traumatic Stress Disorder (PTSD).
Virpax has global rights to use a patented MET formulation to deliver pharmaceutical-grade cannabinol for the management of Epilepsy, a Rare Pediatric Disease.
Virpax has global rights to a patented topical spray film delivery technology for osteoarthritis of the knee.
Virpax has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.